A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. (Q46012889)

From Wikidata

Jump to navigation Jump to search

scientific article published in May 2008

Language	Label	Description	Also known as
English	A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.	scientific article published in May 2008

Statements

scholarly article

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. (English)

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

Philip W. Kantoff

4

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

Mary-Ellen Taplin

1

object named as

Mary-Ellen Taplin

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

2

object named as

Judith Manola

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

author name string

Glenn J Bubley

5

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

Matthew Smith

6

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

Diana Barb

7

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

Christos Mantzoros

8

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

Edward P Gelmann

9

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

Steven P Balk

10

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

publication date

1 May 2008

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

BJU International

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

101

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

9

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

1084-1089

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

Secondary hormonal therapies in the treatment of prostate cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Regulation of androgen receptor signaling in prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Regulation of androgen receptor activity by tyrosine phosphorylation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

The androgen axis in recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Formation of the androgen receptor transcription complex

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

RU486 (mifepristone): mechanisms of action and clinical uses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Current Status of Bilateral Adrenalectomy or Advanced Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07509.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2008.07509.X

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

release_wqznlct77bgqbguem4m56hh5aq

1 reference

https://api.fatcat.wiki/v0/release/wqznlct77bgqbguem4m56hh5aq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/18399827

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46012889&oldid=1966887782"